ENTITY
RemeGen

RemeGen (9995 HK)

312
Analysis
Health Care • China
RemeGen is a China-based biopharmaceutical company dedicated to the discovery, development, production, and commercialization of innovative biological drugs. The company focuses on therapeutic antibody drugs, including antibody-drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies, for major diseases such as autoimmune disorders, oncology, and ophthalmology. Key products include Telitacicept (RC18) and Disitamab Vedotin (RC48). RemeGen was co-founded in 2008 and is headquartered in Yantai, Shandong Province, China.
more
Company Event • 30 Oct 2026 16:00 • Upcoming
Add To Calendar

Q3 2026

Company Event • 25 Mar 2027 09:30 • Upcoming
Add To Calendar

Q4 2026

Company Event • 24 Aug 2026 22:40 • Upcoming
Add To Calendar

Q2 2026

Company Event • 28 Apr 2026 16:00 • Upcoming
Add To Calendar

Q1 2026

Company Event • 27 Mar 2026 15:30 • Upcoming
Add To Calendar

Q4 2025

x